---
pmid: '31634899'
title: FSP1 is a glutathione-independent ferroptosis suppressor.
authors:
- Doll S
- Freitas FP
- Shah R
- Aldrovandi M
- da Silva MC
- Ingold I
- Goya Grocin A
- Xavier da Silva TN
- Panzilius E
- Scheel CH
- Mourão A
- Buday K
- Sato M
- Wanninger J
- Vignane T
- Mohana V
- Rehberg M
- Flatley A
- Schepers A
- Kurz A
- White D
- Sauer M
- Sattler M
- Tate EW
- Schmitz W
- Schulze A
- O'Donnell V
- Proneth B
- Popowicz GM
- Pratt DA
- Angeli JPF
- Conrad M
journal: Nature
year: '2019'
full_text_available: false
doi: 10.1038/s41586-019-1707-0
---

# FSP1 is a glutathione-independent ferroptosis suppressor.
**Authors:** Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, Goya Grocin A, Xavier da Silva TN, Panzilius E, Scheel CH, Mourão A, Buday K, Sato M, Wanninger J, Vignane T, Mohana V, Rehberg M, Flatley A, Schepers A, Kurz A, White D, Sauer M, Sattler M, Tate EW, Schmitz W, Schulze A, O'Donnell V, Proneth B, Popowicz GM, Pratt DA, Angeli JPF, Conrad M
**Journal:** Nature (2019)
**DOI:** [10.1038/s41586-019-1707-0](https://doi.org/10.1038/s41586-019-1707-0)

## Abstract

1. Nature. 2019 Nov;575(7784):693-698. doi: 10.1038/s41586-019-1707-0. Epub 2019 
Oct 21.

FSP1 is a glutathione-independent ferroptosis suppressor.

Doll S(#)(1), Freitas FP(#)(2), Shah R(3), Aldrovandi M(1)(4), da Silva MC(1), 
Ingold I(1), Goya Grocin A(5), Xavier da Silva TN(2), Panzilius E(6), Scheel 
CH(6)(7), Mourão A(8), Buday K(1), Sato M(1), Wanninger J(1), Vignane T(1), 
Mohana V(1), Rehberg M(9), Flatley A(10), Schepers A(10), Kurz A(11), White 
D(4), Sauer M(11), Sattler M(8), Tate EW(5), Schmitz W(12), Schulze A(12), 
O'Donnell V(4), Proneth B(1), Popowicz GM(8), Pratt DA(3), Angeli JPF(13), 
Conrad M(14).

Author information:
(1)Institute of Developmental Genetics, Helmholtz Zentrum München, Neuherberg, 
Germany.
(2)Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, 
Würzburg, Germany.
(3)Department of Chemistry & Biomolecular Sciences, University of Ottawa, 
Ottawa, ON, Canada.
(4)Systems Immunity Research Institute, School of Medicine, Cardiff University, 
Cardiff, UK.
(5)Molecular Sciences Research Hub, Department of Chemistry, Imperial College 
London, London, UK.
(6)Institute of Stem Cell Biology, Helmholtz Zentrum München, Neuherberg, 
Germany.
(7)Clinic for Dermatology, St Josef Hospital Bochum, University of Bochum, 
Bochum, Germany.
(8)Institute of Structural Biology, Helmholtz Zentrum München, Neuherberg, 
Germany.
(9)Institute of Lung Biology and Disease, Helmholtz Zentrum München, Neuherberg, 
Germany.
(10)Monoclonal Antibody Core Facility, Helmholtz Zentrum München, Neuherberg, 
Germany.
(11)Department of Biotechnology & Biophysics, Biocenter, University of Würzburg, 
Würzburg, Germany.
(12)Department of Biochemistry and Molecular Biology, Theodor Boveri Institute, 
Biocenter, University of Würzburg, Würzburg, Germany.
(13)Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, 
Würzburg, Germany. pedro.angeli@virchow.uni-wuerzburg.de.
(14)Institute of Developmental Genetics, Helmholtz Zentrum München, Neuherberg, 
Germany. marcus.conrad@helmholtz-muenchen.de.
(#)Contributed equally

Comment in
    Nature. 2019 Nov;575(7784):597-598. doi: 10.1038/d41586-019-03145-8.
    Cell Res. 2020 Jan;30(1):3-4. doi: 10.1038/s41422-019-0258-0.
    Cell Metab. 2020 Jan 7;31(1):13-15. doi: 10.1016/j.cmet.2019.12.007.
    Mov Disord. 2020 Mar;35(3):400. doi: 10.1002/mds.27990.

Ferroptosis is an iron-dependent form of necrotic cell death marked by oxidative 
damage to phospholipids1,2. To date, ferroptosis has been thought to be 
controlled only by the phospholipid hydroperoxide-reducing enzyme glutathione 
peroxidase 4 (GPX4)3,4 and radical-trapping antioxidants5,6. However, 
elucidation of the factors that underlie the sensitivity of a given cell type to 
ferroptosis7 is crucial to understand the pathophysiological role of ferroptosis 
and how it may be exploited for the treatment of cancer. Although metabolic 
constraints8 and phospholipid composition9,10 contribute to ferroptosis 
sensitivity, no cell-autonomous mechanisms have been identified that account for 
the resistance of cells to ferroptosis. Here we used an expression cloning 
approach to identify genes in human cancer cells that are able to complement the 
loss of GPX4. We found that the flavoprotein apoptosis-inducing factor 
mitochondria-associated 2 (AIFM2) is a previously unrecognized anti-ferroptotic 
gene. AIFM2, which we renamed ferroptosis suppressor protein 1 (FSP1) and which 
was initially described as a pro-apoptotic gene11, confers protection against 
ferroptosis elicited by GPX4 deletion. We further demonstrate that the 
suppression of ferroptosis by FSP1 is mediated by ubiquinone (also known as 
coenzyme Q10, CoQ10): the reduced form, ubiquinol, traps lipid peroxyl radicals 
that mediate lipid peroxidation, whereas FSP1 catalyses the regeneration of 
CoQ10 using NAD(P)H. Pharmacological targeting of FSP1 strongly synergizes with 
GPX4 inhibitors to trigger ferroptosis in a number of cancer entities. In 
conclusion, the FSP1-CoQ10-NAD(P)H pathway exists as a stand-alone parallel 
system, which co-operates with GPX4 and glutathione to suppress phospholipid 
peroxidation and ferroptosis.

DOI: 10.1038/s41586-019-1707-0
PMID: 31634899 [Indexed for MEDLINE]
